AccScience Publishing / AN / Volume 1 / Issue 2 / DOI: 10.36922/an.v1i2.71

Associations of common variants in TAAR5, OR6C70, and GBA with hyposmia in Han Chinese individuals with Parkinson’s disease

Yi-Lun Ge1 Pu-Zhi Wang1 Jia-Hui Yan1 Wen Li1 Jin-Ru Zhang1 Hong Jin1 Ya-Ping Yang1 Fen Wang2 Dan Li3 Jing Chen1 Kai Li1* Cheng-Jie Mao1,3* Chun-Feng Liu1,2,3
Show Less
1 Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 Institute of Neuroscience, Soochow University, Suzhou, Jiangsu, China
3 Department of Neurology, Suqian First Hospital, Suqian, China
Advanced Neurology 2022, 1(2), 71
Submitted: 17 April 2022 | Accepted: 31 May 2022 | Published: 27 July 2022
© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Hyposmia is one of the cardinal symptoms of Parkinson’s disease (PD), with a considerably high prevalence rate in PD individuals. However, some individuals still retain normal olfactory function. Recent studies have shown that genetic factors may play a role in such a phenomenon. This study aimed to explore the potential genetic factors underlying the variation of olfactory function among PD individuals. Two hundred and three Han Chinese individuals with PD were recruited into this study. All the individuals underwent detailed clinical assessment conducted by experienced neurologists. High-throughput sequencing was performed to identify gene variants associated with PD. TAAR5, OR6C70, and GBA were included in the association analysis. In our study, 85 out of 203 individuals (41.9%) reported normal olfaction, and the other 118 (58.1%) reported hyposmia. Genotype and allele logistic regression models were applied to association analysis. We did not find any significant association of TAAR5 and OR6C70 with hyposmia. However, we found that GBA rs762488 was associated with increased hyposmia risk (P = 0.036, OR = 3.05, 95% CI = 1.08–8.63), while GBA rs1800438 was associated with decreased hyposmia risk (P = 0.032, OR = 0.47, 95% CI = 0.24–0.94). In conclusion, this study revealed the association of GBA with hyposmia, indicating the genetic involvement in PD hyposmia variation. However, we did not replicate previous results (TAAR5 and OR6C70) in this study. Further studies with larger sample sizes in different populations are warranted.

Parkinson’s disease
National Key R&D Program of China
Jiangsu Provincial Key R&D Program
Jiangsu Provincial Medical Key Discipline Project
Suzhou Clinical Research Center of Neurological Disease
National Natural Science Foundation of China
Talent Support Project for Science and Teaching of the Second Affiliated Hospital of Soochow University
Pre-research Project for Doctors of the Second Affiliated Hospital of Soochow University

Doty RL, 2012, Olfactory dysfunction in Parkinson disease. Nat Rev Neuro, 8(6): 329–339. 


Mesholam RI, Moberg PJ, Mahr RN, et al., 1998, Olfaction in neurodegenerative disease: A meta-analysis of olfactory functioning in Alzheimer’s and parkinson’s diseases. Arch Neuro, 55(1): 84–90. 


Marin C, Vilas D, Langdon C, et al., 2018, Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep, 18(8): 42.


Haehner A, Boesveldt S, Berendse HW, et al., 2009, Prevalence of smell loss in Parkinson’s disease-a multicenter study. Parkinsonism Relat Disord, 15(7): 490–494.


Rossi M, Escobar AM, Bril A, et al., 2016, Motor features in Parkinson’s disease with normal olfactory function. Mov Disord, 31(9): 1414–1417.


Gisladottir RS, Ivarsdottir EV, Helgason A, et al., 2020, Sequence variants in TAAR5 and other loci affect human odor perception and naming. Curr Biol, 30(23): 4643–4653.


Sobhani S, Rahmani F, Aarabi MH, et al., 2019, Exploring white matter microstructure and olfaction dysfunction in early parkinson disease: Diffusion MRI reveals new insight. Brain Imaging Behav, 13(1): 210–219. 


Thaler A, Bregman N, Gurevich T, et al., 2018, Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord, 55: 45–49.


Da Silva CP, Aberu GD, Acero PH, et al., 2017, Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson’s disease. J Neurolo Sci, 381: 160–164.


Postuma RB, Berg D, Stern M, et al., 2015, MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord, 30(12): 1591–1601.


Daniel SE, Lees AJ, 1993, Parkinson’s disease society brain bank, London: overview and research. J Neural Transm Suppl, 39: 165–172.


Martínez-Martín P, Gil-Nagel A, Gracia LM, et al., 1994, Unified parkinson’s disease rating scale characteristics and structure. The cooperative multicentric group. Mov Disord, 9(1): 76–83. 


Tomlinson CL, Stowe R, Patel S, et al., 2010, Systematic review of levodopa dose equivalency reporting in parkinson’s disease. Mov Disord, 25(15): 2649–2653.


Chaudhuri KR, Martinez-Martin P, Schapira AH, et al., 2006, International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for parkinson’s disease: The NMSQuest study. Mov Disord, 21(7): 916–923.


Cecchini MP, Federico A, Zanini A, et al., 2019, Olfaction and taste in parkinson’s disease: The association with mild cognitive impairment and the single cognitive domain dysfunction. J Neural Transm (Vienna), 126(5): 585–595.


Li K, Ge YL, Gu CC, et al., 2020, Substantia nigra echogenicity is associated with serum ferritin, gender and iron-related genes in parkinson’s disease. Sci Rep, 10(1): 8660.


Zhang JR, Jin H, Li K, et al., 2018, Genetic analysis of LRRK2 in Parkinson’s disease in Han Chinese population. Neurobiol Aging, 72: 187.e5–187.e10.


Shi YY, He L, 2005, SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res, 15(2): 97–98.


Ascherio A, Schwarzschild MA, 2016, The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol, 15(12): 1257–1272.


Cheng XY, Mao CJ, Wang YL, et al., 2022, Gastrointestinal symptoms of Parkinson’s disease: A systematic review from pathogenesis to management. Adv Neurol, 1(1): 53.


Boesveldt S, Verbaan D, Knol D, et al., 2007, Assessment of odor identification and discrimination in dutch parkinson’s disease patients. Mov Disord, 22: S161.


Bohnen NI, Gedela S, Kuwabara H, et al., 2007, Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease. J Neurol, 254(1): 84–90.


Double KL, Rowe DB, Hayes M, et al., 2003, Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol, 60(4): 545–549.


Espinoza S, Sukhanov I, Efimova EV, et al., 2020, trace amine-associated receptor 5 provides olfactory input into limbic brain areas and modulates emotional behaviors and serotonin transmission. Front Mol Neurosci, 13: 18.


Efimova EV, Kozlova AA, Razenkova V, et al., 2021, Increased dopamine transmission and adult neurogenesis in trace amine-associated receptor 5 (TAAR5) knockout mice. Neuropharmacology, 182: 108373.


Kalia LV, Lang AE, 2015, Parkinson’s disease. Lancet, 386(9996): 896–912.


Doty RL, Deems DA, Stellar S, 1988, Olfactory dysfunction in Parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology, 38(8): 1237–1244.


Jiang RS, Su MC, Liang KL, et al., 2010, A pilot study of a traditional Chinese version of the University of Pennsylvania smell identification test for application in Taiwan. Am J Rhinol Allergy, 24(1): 45–50.


Rabin MD, 1988, Experience facilitates olfactory quality discrimination. Percept Psychophys, 44(6):532–540.

Conflict of interest
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Published by AccScience Publishing